https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29346 Wed 23 Feb 2022 16:04:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16753 Wed 11 Apr 2018 15:29:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31828 Wed 09 Mar 2022 16:00:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46465 n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. Results: Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade=2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade=2 tenesmus and increased low-intermediate dose (~25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). Conclusions: The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.]]> Thu 24 Nov 2022 15:46:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38985 n = 11), pain/cramping (n = 9) and bloating/flatulence (n = 5). Three studies stated an improvement in diarrhoea incidence. Results varied between studies. Further quality studies are required to assess the effectiveness of DC, in particular individualised DC on GI toxicities in patients receiving pelvic RT.]]> Thu 24 Mar 2022 16:11:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21106 Sat 24 Mar 2018 07:53:59 AEDT ]]>